Study summary
YL201 shrank tumors across several cancers
41%of tumors shrank, all cancers combined
What was tested
YL201, an antibody-drug conjugate aimed at B7-H3, in people with advanced solid tumors after other treatments. No comparison group.
What they found
- Tumors shrank in 40.8% of 287 people; 83.6% had their cancer shrink or hold steady.
- Best results were in small cell lung cancer (64%) and nasopharyngeal cancer (49%).
- A figure for esophageal cancer alone was not in the reports we found.
What it means
Enough to start a 440-person phase 3 in this cancer, finishing around April 2028.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.